Cerus Corporation (CERS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cerus Corporation (CERS) has a cash flow conversion efficiency ratio of -0.045x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.05 Million) by net assets ($68.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CERS company net worth for the company's overall valuation and market capitalisation.
Cerus Corporation - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Cerus Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cerus Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cerus Corporation ranked by their cash flow conversion efficiency. Explore CERS operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
0.034x |
|
Coca-Cola Embonor S.A
SN:EMBONOR-B
|
0.050x |
|
Amos Luzon Development and Energy Group Ltd
TA:LUZN
|
-0.056x |
|
Anhui Ankai Automobile Co Ltd
SHE:000868
|
0.002x |
|
Nanjing Bestway Intelligent Control Technology Co. Ltd. A
SHE:301195
|
N/A |
|
Invesco Municipal Trust
NYSE:VKQ
|
0.022x |
|
Beijing Dinghan Tech Co
SHE:300011
|
-0.015x |
|
Shenzhen Sunyes Electronic Manufacturing Holding Co Ltd
SHE:002388
|
-0.066x |
Annual Cash Flow Conversion Efficiency for Cerus Corporation (1997–2025)
The table below shows the annual cash flow conversion efficiency of Cerus Corporation from 1997 to 2025. View CERS stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.97 Million | $11.36 Million | 0.175x | -12.42% |
| 2024-12-31 | $56.90 Million | $11.36 Million | 0.200x | +124.72% |
| 2023-12-31 | $53.44 Million | $-43.17 Million | -0.808x | -116.20% |
| 2022-12-31 | $68.56 Million | $-25.61 Million | -0.374x | +5.70% |
| 2021-12-31 | $85.62 Million | $-33.92 Million | -0.396x | +1.63% |
| 2020-12-31 | $103.81 Million | $-41.81 Million | -0.403x | +64.92% |
| 2019-12-31 | $57.05 Million | $-65.50 Million | -1.148x | -210.54% |
| 2018-12-31 | $84.52 Million | $-31.25 Million | -0.370x | +72.44% |
| 2017-12-31 | $38.94 Million | $-52.23 Million | -1.341x | -44.81% |
| 2016-12-31 | $57.79 Million | $-53.53 Million | -0.926x | -71.69% |
| 2015-12-31 | $94.77 Million | $-51.13 Million | -0.540x | +43.47% |
| 2014-12-31 | $41.71 Million | $-39.81 Million | -0.954x | -52.43% |
| 2013-12-31 | $42.80 Million | $-26.80 Million | -0.626x | +14.03% |
| 2012-12-31 | $19.11 Million | $-13.92 Million | -0.728x | +14.67% |
| 2011-12-31 | $18.31 Million | $-15.63 Million | -0.854x | -43.56% |
| 2010-12-31 | $23.73 Million | $-14.11 Million | -0.595x | +13.03% |
| 2009-12-31 | $21.45 Million | $-14.66 Million | -0.684x | +32.16% |
| 2008-12-31 | $34.28 Million | $-34.55 Million | -1.008x | -61.36% |
| 2007-12-31 | $59.89 Million | $-37.40 Million | -0.625x | -329.42% |
| 2006-12-31 | $100.97 Million | $-14.69 Million | -0.145x | +65.68% |
| 2005-12-31 | $35.27 Million | $-14.95 Million | -0.424x | +28.46% |
| 2004-12-31 | $21.49 Million | $-12.73 Million | -0.592x | +46.92% |
| 2003-12-31 | $52.53 Million | $-58.62 Million | -1.116x | -12.62% |
| 2002-12-31 | $56.17 Million | $-55.65 Million | -0.991x | -140.40% |
| 2001-12-31 | $106.75 Million | $-44.00 Million | -0.412x | -5.41% |
| 2000-12-31 | $81.92 Million | $-32.03 Million | -0.391x | +61.25% |
| 1999-12-31 | $33.00 Million | $-33.30 Million | -1.009x | +86.48% |
| 1998-12-31 | $1.30 Million | $-9.70 Million | -7.462x | -911.35% |
| 1997-12-31 | $22.50 Million | $-16.60 Million | -0.738x | -- |
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offer… Read more